BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 2981838)

  • 1. Covalent cross-linking of vasoactive intestinal polypeptide to its receptors on intact human lymphoblasts.
    Wood CL; O'Dorisio MS
    J Biol Chem; 1985 Jan; 260(2):1243-7. PubMed ID: 2981838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of receptors for VIP on pancreatic acinar cell plasma membranes using covalent cross-linking.
    McArthur KE; Wood CL; O'Dorisio MS; Zhou ZC; Gardner JD; Jensen RT
    Am J Physiol; 1987 Mar; 252(3 Pt 1):G404-12. PubMed ID: 2435170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonic epithelium.
    Couvineau A; Laburthe M
    J Clin Endocrinol Metab; 1985 Jul; 61(1):50-5. PubMed ID: 2987295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Covalent cross-linking of vasoactive intestinal peptide (VIP) to its receptor in intact colonic adenocarcinoma cells in culture (HT 29).
    Muller JM; Luis J; Fantini J; Abadie B; Giannellini F; Marvaldi J; Pichon J
    Eur J Biochem; 1985 Sep; 151(2):411-7. PubMed ID: 2992966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rat liver vasoactive intestinal peptide binding site. Molecular characterization by covalent cross-linking and evidence for differences from the intestinal receptor.
    Couvineau A; Laburthe M
    Biochem J; 1985 Jan; 225(2):473-9. PubMed ID: 3977841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells.
    Gespach C; Bawab W; de Cremoux P; Calvo F
    Cancer Res; 1988 Sep; 48(18):5079-83. PubMed ID: 2842044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular identification of receptors for vasoactive intestinal peptide in rat intestinal epithelium by covalent cross-linking. Evidence for two classes of binding sites with different structural and functional properties.
    Laburthe M; Breant B; Rouyer-Fessard C
    Eur J Biochem; 1984 Feb; 139(1):181-7. PubMed ID: 6321173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demonstration of a functional receptor for vasoactive intestinal polypeptide on Molt 4b T lymphoblasts.
    Beed EA; O'Dorisio MS; O'Dorisio TM; Gaginella TS
    Regul Pept; 1983 Apr; 6(1):1-12. PubMed ID: 6306732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HT 29, a model cell line: stimulation by the vasoactive intestinal peptide (VIP); VIP receptor structure and metabolism.
    Marchis-Mouren G; Martin JM; Luis J; el Battari A; Muller JM; Marvaldi J; Pichon J
    Biochimie; 1988 May; 70(5):663-71. PubMed ID: 2844304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characteristics and peptide specificity of vasoactive intestinal peptide receptors from rat cerebral cortex.
    Couvineau A; Gammeltoft S; Laburthe M
    J Neurochem; 1986 Nov; 47(5):1469-75. PubMed ID: 3020175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Affinity labeling of the sialoglycopeptide antimitogen receptor.
    Sharifi BG; Johnson TC
    J Biol Chem; 1987 Nov; 262(32):15752-5. PubMed ID: 3680224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for the formation of a functional complex between vasoactive intestinal peptide, its receptor, and Gs in lung membranes.
    Kermode JC; DeLuca AW; Zilberman A; Valliere J; Shreeve SM
    J Biol Chem; 1992 Feb; 267(5):3382-8. PubMed ID: 1310685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29.
    Couvineau A; Rousset M; Laburthe M
    Biochem J; 1985 Oct; 231(1):139-43. PubMed ID: 2998337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of vasoactive intestinal peptide receptors on human megakaryocytes and platelets.
    Park SK; Olson TA; Ercal N; Summers M; O'Dorisio MS
    Blood; 1996 Jun; 87(11):4629-35. PubMed ID: 8639831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasoactive intestinal peptide effects on GH3 pituitary tumor cells: high affinity binding, affinity labeling, and adenylate cyclase stimulation. Comparison with peptide histidine isoleucine and growth hormone-releasing factor.
    Wood CL; O'Dorisio MS; Vassalo LM; Malarkey WB; O'Dorisio TM
    Regul Pept; 1985 Nov; 12(3):237-48. PubMed ID: 3001842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solubilization of the active vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells.
    el Battari A; Martin JM; Luis J; Pouzol O; Secchi J; Marvaldi J; Pichon J
    J Biol Chem; 1988 Nov; 263(33):17685-9. PubMed ID: 2846575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and solubilization of vasoactive intestinal peptide receptors from rat lung membranes.
    Provow S; Veliçelebi G
    Endocrinology; 1987 Jun; 120(6):2442-52. PubMed ID: 3032591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasoactive intestinal peptide receptor on liver plasma membranes: solubilization and cross-linking.
    Nguyen TD; Kaiser LM
    Peptides; 1990; 11(6):1255-61. PubMed ID: 1965036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Affinity labeling of multiplication stimulating activity receptors in membranes from rat and human tissues.
    Massague J; Guillette BJ; Czech MP
    J Biol Chem; 1981 Mar; 256(5):2122-5. PubMed ID: 6257700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-linking of a growth hormone releasing factor-binding protein in anterior pituitary cells.
    Zysk JR; Cronin MJ; Anderson JM; Thorner MO
    J Biol Chem; 1986 Dec; 261(36):16781-4. PubMed ID: 3023363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.